Novel Parkinson’s Disease Drug Will Join AbbVie With Positive Phase 3 Data In Hand
An experimental Parkinson’s disease drug, tavapadon, has shown promising results in a pivotal study conducted by Cerevel Therapeutics. The drug led to a longer time of motor symptom control in patients with Parkinson’s, with statistically significant increases in “on” time. Tavapadon targets specific dopamine receptors in the brain, aiming to provide better motor control with…